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Background: This multicenter, randomized, double-blind, double-dummy, placebo-controlled trial primarily
evaluated the efficacy of tadalafil once-daily (OaD) or on-demand (“pro-re-nata”; PRN) treatment, started early
post-nsRP. Secondary outcome-measures on quality-of-life (QoL) and treatment satisfaction are reported.
Methods: Patients, aged <68 yrs, with adenocarcinoma of the prostate (Gleason ≤ 7, normal preoperative erectile
function [EF]) were randomized post-nsRP 1:1:1 to 9-month treatment with tadalafil 5 mg OaD, tadalafil 20 mg
PRN, or placebo, followed by 6-week drug-free washout and 3-month open-label tadalafil OaD treatment (OLT).
The main outcome measures were Changes in Expanded Prostate Cancer Index Composite (EPIC-26), Erectile
Dysfunction Inventory of Treatment Satisfaction (EDITS), and Self-Esteem and Relationship (SEAR) questionnaires
(mixed-model-for-repeated-measures, including terms for treatment, visit, treatment-by-visit interaction, age-group,
country, baseline-score). LS means with 95% confidence interval (CI) are reported.
Results: 423 patients were randomized to 3 treatment-groups: tadalafil OaD (N = 139), PRN (N = 143), or placebo
(N = 141). In each group, 57 (41.0%), 58 (40.6%), and 50 (35.5%) patients were aged 61-68 yrs. At the end of double-blind
treatment (DBT), patients’ EPIC sexual domain-scores improved significantly with tadalafil OaD versus placebo
(treatment effect [95% CI]: 9.6 [3.1,16.0]; p = 0.004); comparisons of PRN versus placebo at end of DBT, and comparisons of
tadalafil OaD and PRN versus placebo after OLT were not significant. Only in older patients (61-68 yrs; age-by-treatment
p ≤ 0.1), EPIC urinary incontinence domain-scores also improved significantly with tadalafil OaD versus placebo
(overall treatment effect across all visits, 8.3 [0.4,16.1]; p = 0.040). Treatment satisfaction increased significantly in
both tadalafil groups, EDITS total-scores increased significantly with OaD and PRN versus placebo during DBT (p = 0.005
and p = 0.041, respectively). At the end of OLT, improvement was significant for tadalafil OaD versus placebo only
(p = 0.035). No significant differences were observed for SEAR.
Conclusions: These results suggest that chronic dosing of tadalafil improves QoL of patients post-nsRP. The
improvement of urinary incontinence in elderly patients randomized to tadalafil OaD may contribute to this effect.
Trial registration: www.clinicaltrials.gov, NCT01026818.
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Erectile dysfunction (ED) is a common problem after
nerve-sparing radical prostatectomy (nsRP) for localized
prostate cancer [1,2]. First-line therapy for ED after nsRP
is the use of a phosphodiesterase type 5 (PDE5) inhibitor
[3]. Alternative treatment options include intracavernosal
injections, e.g., of the “trimix” combination of alprostadil,
phentolamine, and papaverine, intrautheral alprostadil
suppositories, vacuum erection devices, or inflatable penile
prosthesis [3]. PDE5 inhibitors are generally well-tolerated
and effective treatments of ED after nsRP, although they are
less effective in the post-nsRP population than in the gen-
eral population [1,4,5]. There is still considerable debate as
to which patients might benefit most from PDE5 inhibitor
treatment after nsRP, and what would be the optimal time
for treatment initiation, the optimal duration of treatment,
and the most appropriate efficacy endpoints [6].
To date, there have been 4 randomized controlled trials
evaluating the impact of the early use of PDE5 inhibitors
in men with ED following nsRP. Nightly administration of
sildenafil for 36 weeks, starting 4 weeks after surgery,
markedly increased the return of normal spontaneous
erections; the study was stopped early since it was ex-
pected not to meet its primary endpoint [7]. Vardenafil
treatment for 9 months, starting within 2 weeks after sur-
gery, was efficacious when used on-demand (pro-re-nata,
PRN), but had no significant effect on unassisted erectile
function (EF) after drug-free washout [5]. In a recent
study, 3 months of treatment with avanafil 100 or 200 mg
PRN significantly improved drug-assisted EF after prosta-
tectomy, but a sustained effect on unassisted EF was not
assessed [8]. Finally, the REACTT trial has evaluated the
effect of the long-acting PDE5 inhibitor tadalafil, showing
that tadalafil once daily [OaD] was most effective on drug-
assisted EF during 9 months of double-blind treatment
(DBT) [9]. The study suggested a potential role of tadalafil
OaD provided early after surgery in contributing to EF
recovery, and a significant protection from penile length
loss, possibly by protecting from penile structural changes.
However, also in this trial, unassisted EF was not improved
after drug-free washout following DBT [9].
These post-nsRP studies have predominantly looked
at standard ED outcomes, including the International
Index of Erectile Function (IIEF) domain scores and
Sexual Encounter Profile (SEP) questions. However,
prostate cancer patients frequently report other associ-
ated symptoms, e.g., penile length loss, climacturia, or
urinary incontinence, which may have a pronounced
impact on their quality of life (QoL).
This manuscript addresses secondary outcome measures
on QoL and treatment satisfaction in early post-nsRP
patients who participated in the REACTT trial [9]. The
QoL questionnaires used evaluate those aspects of QoL
which are specifically relevant for prostate cancer patientsand patients with ED, for example the Expanded Prostate
Cancer Index Composite Short Form (EPIC-26) [10,11].
This questionnaire addressed 4 different domains — sex-
ual, urinary (divided into incontinence and irritation/ob-
struction subscales), bowel, and hormonal function [10,11].
The sexual and urinary incontinence domain scores are
the most relevant to QoL of post-nsRP prostate cancer pa-
tients, as ED and urinary incontinence are common seque-
lae of nsRP [12,13]; other subscales are more pertinent to
prostate cancer patients who have had radiation or hormo-
nal deprivation therapy. This study also used the Erectile
Dysfunction Inventory of Treatment Satisfaction (EDITS)
questionnaire to assess patient and partner satisfaction
with ED treatment, and the Self-Esteem and Relationship
(SEAR) instrument, which assessed patient and partner
sexual relationship confidence and self-esteem [14,15].
Methods
Patients
All enrolled patients were adult men, aged < 68 years at
the time of nsRP, with normal preoperative EF (IIEF-EF
domain score ≥ 22) [9] who underwent nsRP for
organ-confined, non-metastatic prostate cancer (Glea-
son score ≤ 7, prostate specific antigen <10 ng/mL).
These patients were enrolled between November 2009
and August 2011, in 50 centers in 9 European countries
and Canada; detailed trial design and eligibility criteria
are available at www.clinicaltrials.gov (NCT01026818)
and in [9]. The study was approved by the responsible
ethical review boards (Additional file 1: Table S1).
Trial design
This multicenter, Phase IV, randomized, double-blind, 3-
arm, placebo-controlled, parallel-group trial was con-
ducted in accordance with the declaration of Helsinki;
appropriate ethical review boards approved the study
protocol for each country. All patients signed written in-
formed consent. The trial consisted of a screening period
(including nsRP), 9 months of randomized, double-blind,
double-dummy, treatment with tadalafil 5 mg OaD,
tadalafil 20 mg PRN, or placebo, starting within 6 weeks
after nsRP (double-blind treatment; DBT), 6 weeks of
drug-free washout, and 3 months of open-label treatment
with tadalafil 5 mg OaD (OLT, all patients) (Additional
file 1: Figure S1). Matching placebo tablets identical to
the 5 mg and 20 mg tadalafil tablets were used to ensure
that the blinded regimen was identical for all treatment
groups. During DBT, patients received tadalafil 5 mg
OaD (+ placebo PRN), tadalafil 20 mg PRN (+ placebo
OaD) or placebo (OaD + PRN). For PRN dosing, patients
were permitted to take up to 3 tablets per week (and no
more than 1 per day). During drug-free washout, patients
received no study drug. During the open-label period, all
patients received tadalafil 5 mg OaD.
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Patients’ EF was assessed using the IIEF-EF domain
score at baseline (post-nsRP), the end of DBT, and the
end of OLT [16].
EPIC-26 domain scores [10,11], with a special focus
on the sexual and urinary incontinence domain scores,
were used to assess patients’ prostate-specific QoL status
at baseline, the end of DBT, and the end of OLT. In
addition, partners were asked to complete the EPIC-26P
questionnaire. Individual item and EPIC domain scores
were standardized to a 0 to 100 scale; higher scores
represent better QoL [10,11].
The 11-item EDITS questionnaire was used to assess
patients’ treatment satisfaction at the end of DBT and
OLT [14]. Responses were based on the 4 weeks preceding
assessments. Each question was rated from 0 to 4 withTable 1 Baseline characteristics
Tadalafil OaD (N = 139) Tadal
Age, years
Mean (SD) 58.6 (5.07) 57.5 (5
<61 years, n (%) 82 (59.0) 85 (5
61-68 years, n (%) 57 (41.0) 58 (4
nsRP approach, n (%)
Open surgery 68 (48.9) 65 (4
Conventional laparoscopy 29 (20.9) 31 (2
Robot-assisted laparoscopy 31 (22.3) 41 (2
Other 11 (7.9) 6 (4
IIEF-EF at randomization (V4, after prostatectomy)
N with data 137
Mean (SD) 6.0 (5.80) 6.7 (5
EPIC sexual domain score
N with data 133
Mean (SD) 19.8 (19.56) 21.9 (2
EPIC urinary incontinence domain score
N with data 133
Mean (SD) 46.7 (30.71) 47.9 (2
EPIC urinary irritative/obstructive domain score
N with data 131
Mean (SD) 78.1 (18.92) 81.5 (1
EPIC bowel domain total score
N with data 129
Mean (SD) 88.3 (15.32) 91.2 (1
EPIC hormonal domain score
N with data 130
Mean (SD) 90.0 (12.71) 92.0 (1
aData presented for all patients randomized. One patient assigned to tadalafil PRN did
Abbreviations: EPIC Expanded Prostate Cancer Index Composite (EPIC-26), IIEF-EF Int
number of patients, n number of patients with characteristic, nsRP bilateral nerve-sp
“pro-re-nata”/on-demand, SD standard deviation, V visit EPIC scores range from 0–1higher scores indicating higher satisfaction, and the total
score (average of the individual item scores) was reported.
The SEAR questionnaire was used to assess the patients’
sexual relationships and self-esteem at baseline, the end of
DBT, and the end of OLT [15]. The SEAR questionnaire
has 2 domains of sexual relationship (domain score range
8 to 40) and confidence (range 6 to 30), the latter of these
domains can be divided into 2 subscales on self-esteem
(range 4 to 20) and overall relationship (range 2 to 10)
[15]. Higher scores indicate a more favorable response.
Statistical analysis
The planned sample size of 412 patients was based on
the primary outcome (proportion of patients achieving
IIEF-EF ≥22) at the end of drug-free washout period [9].
All analyses were based on the intent-to-treat (ITT)afil PRN (N = 143)a Placebo (N = 141) Overall (N = 423)a
.91) 57.6 (5.69) 57.9 (5.58)
9.4) 91 (64.5) 258 (61.0)
0.6) 50 (35.5) 165 (39.0)
5.5) 56 (39.7) 189 (44.7)
1.7) 28 (19.9) 88 (20.9)
8.7) 44 (31.2) 116 (27.4)
.2) 13 (9.2) 30 (7.1)
140 137 414
.57) 6.5 (6.08) 6.4 (5.81)
140 137 410
0.16) 20.1 (21.87) 20.6 (20.53)
139 137 409
8.89) 49.5 (28.05) 48.0 (29.17)
137 134 402
5.08) 81.3 (16.42) 80.4 (16.88)
134 136 399
0.31) 89.9 (13.69) 89.8 (13.27)
137 136 403
0.51) 91.4 (10.89) 91.2 (11.39)
not receive any study drug and was therefore not included in the ITT population.
ernational Index of Erectile Function – Erectile Function, ITT intent-to-treat, N
aring prostatectomy, NSS Nelson Nerve-Sparing score, OaD once daily, PRN
00, higher scores indicate better values.
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baseline data and at least 1 post-baseline visit. Pre-
specified treatment group comparisons were tadalafil
OaD versus placebo and tadalafil PRN versus placebo.
Changes from baseline in EPIC and SEAR domain
scores, and actual EDITS total scores were assessed
using a pre-specified mixed model for repeated measures
(MMRM), assuming an unstructured covariance matrix
and included terms for baseline domain score, treat-
ment, country, visit, visit-by-treatment interaction, age
group, and age-group-by treatment interaction (included
only if p < 0.1). Least squares means (LS mean) changes
from baseline and the associated 95% CIs were provided
for the 2 key visits (end of DBT and end of OLT). In case of
a significant age-group by treatment interaction (p < 0.1),
the overall treatment effect (across all visits) by age
group was also provided. Agreement between patient-
and partner-rated EPIC scores was assessed using
unweighted Cohen’s kappa statistics, which is adjusted
for agreement by chance.
Spearman rank correlation coefficients and the associ-
ated 95% CIs were calculated post-hoc to assess correla-
tions at baseline, end of DBT, and end of OLT between:
(a) EPIC sexual and urinary incontinence domain scores;Table 2 LS mean changes [95%CI] in EPIC domain scores from
Tadalafil OaD (N = 139)
EPIC sexual domain (age-group by treatment interaction: p = 0.083)a
End of DBT +27.5 [21.6, 33.4]**
End of OLT +36.6 [30.0, 43.1]
Men ≤60 years +30.1 [23.2, 36.9]
Men 61–68 years +34.0 [26.0, 42.0]
EPIC urinary incontinence domain (age-group by treatment interaction: p =
End of DBT +34.1 [29.3, 38.9]
End of OLT +37.4 [32.6, 42.3]
Men ≤60 years +33.0 [27.7, 38.3]
Men 61–68 years +38.5 [32.2, 44.8]*
EPIC urinary irritative/obstructive domain
End of DBT +13.8 [11.5, 16.1]
End of OLT +13.9 [11.5, 16.2]
EPIC bowel domain
End of DBT +5.9 [3.7, 8.2]
End of OLT +6.9 [4.7, 9.1]
EPIC hormonal domain
End of DBT +1.7 [−0.8, 4.3]
End of OLT +2.5 [0.1, 4.9]
**p < 0.01, *p < 0.05 versus placebo (MMRM).
aSignificant at the 10% level.
Abbreviations: CI confidence interval, DBT double-blind treatment, EPIC Expanded Pr
mixed model for repeated measures, N number of patients in the ITT population, O
Data are from MMRM, including baseline domain score, treatment, country, visit, vis
(combined sexual/ incontinence score: additionally adjusted for body mass index, s
robot-assisted, other]). Age-group-by-treatment interaction was included only if sign
italics), the overall treatment effect presented includes all visits from baseline to en(b) IIEF-EF scores and EPIC sexual and urinary incon-
tinence domain scores.
A 2-sided 5% level of significance was used for
p-values for treatment group comparisons; a 10% level
of significance was used for p-values for interaction terms.
No other adjustments for multiplicity were applied for the
analyses reported here. Data were analyzed using SAS 9.2
software (SAS Institute Inc., Cary, USA).
Results
Patient disposition and baseline characteristics
Of 583 patients screened, 423 were randomized to DBT,
422 were included in the ITT population: 139 (32.9%)
patients were treated with tadalafil OaD, 142 (33.7%) with
tadalafil PRN, and 141 (33.4%) with placebo (Additional
file 1: Figure S2). Patient disposition, baseline demographics
[12], and relevant disease characteristics were balanced in
the 3 treatment groups (Table 1). As per inclusion criteria,
all patients had IIEF-EF domain scores ≥22 before nsRP.
EPIC domain scores – patient rating
EPIC sexual and urinary domain scores improved in all
3 treatment groups during DBT and continued to improve
during OLT (Table 2). EPIC sexual domain scores improvedbaseline
Tadalafil PRN (N = 142) Placebo (N = 141)
+20.7 [15.3, 26.1] +18.0 [12.1, 23.8]
+32.6 [26.6, 38.6] +33.4 [27.0, 39.8]
+31.2 [24.8, 37.6] +24.9 [18.2, 31.6]
+22.1 [14.6, 29.5] +26.5 [18.5, 34.4]
0.084)a
+31.1 [26.7, 35.5] +30.6 [25.9, 35.3]
+35.5 [31.1, 40.0] +35.4 [30.7, 40.2]
+34.6 [29.6, 39.7] +35.8 [30.5, 41.1]
+32.0 [26.2, 37.9] +30.2 [24.0, 36.5]
+13.3 [11.2, 15.4] +12.3 [10.0, 14.5]
+13.8 [11.7, 15.9] +12.3 [10.0, 14.6]
+6.3 [4.2, 8.3] +6.5 [4.3, 8.7]
+6.5 [4.5, 8.5] +6.8 [4.6, 8.9]
+2.7 [0.4, 5.1]* −0.2 [−2.7, 2.3]
+2.9 [0.8, 5.1] +3.0 [0.7, 5.4]
ostate Cancer Index Composite (EPIC-26), LS mean least squares mean, MMRM
aD once daily, OLT open-label treatment, PRN “pro-re-nata”/on-demand.
it-by-treatment interaction, and age group (men ≤60 years, men 61–68 years)
moking status, nerve-sparing score, and type of surgery [open, conventional,
ificant at the 10% level. For men ≤60 years and 61–68 years (data shown in
d of OLT.
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the end of DBT (Figure 1; treatment group difference
[95% CI]: 9.6 [3.1, 16.0]; p = 0.004), but not with tada-
lafil PRN versus placebo. The difference between
groups was no longer significant at the end of OLT, i.e.
after all patients had received tadalafil OaD treatment
for 3 months (3.2 [−4.3, 10.7]; p = 0.406). There was
no significant difference in EPIC domain scores be-
tween the PRN and placebo group at the end of DBT



























































































Figure 1 EPIC Sexual Domain Score Changes from Baseline: (a) at the end
in younger (<61 years) versus older (61–68 years) patients, as estimated from
country, visit, visit-by-treatment interaction, age group, and age-group-by-trea
better values.No significant group differences between tadalafil OaD
and placebo were observed for the other EPIC domain
scores (Figure 2).
A significant interaction (p ≤ 0.1) between age group
and treatment was observed for EPIC sexual (p = 0.083)
and urinary incontinence (p = 0.084) domain scores. In
older patients (61-68 years), EPIC urinary incontinence
domain scores improved significantly with tadalafil OaD
versus placebo (Figure 3; overall treatment effect across






of DBT (Month 9) and OLT (Month 13.5), and (b) overall mean change
MMRM. MMRM model adjusted for baseline domain score, treatment,
tment interaction. EPIC scores range from 0–100; higher scores indicate
LSmean treatment group difference [95%CI] of score changes versus placebo
Tadalafil OaD Tadalafil PRN
Score End of DBT 
(Month 9)
End of OLT 
(Month 13.5)
End of DBT 
(Month 9)
End of OLT 
(Month 13.5)
IIEF-EF +2.8 [0.8,4.8]** +1.6 [-0.8, +4.0], n.s. +1.6 [-0.4,+3.6], n.s. +0.8 (-1.5,+3.2], n.s.
EPIC 
Sexual function +9.6 [3.1,16.0]** +3.2 [-4.3,10.7], n.s. +2.7 [-3.6,+9.0], n.s. -0.8 [-8.1,+6.5], n.s.
Urinary incontinence +3.5 [-1.8,+8.8], n.s. +2.0 [-3.5,+7.4], n.s. +0.5 [-4.7,+5.8], n.s. +0.1 [-5.2,+5.4], n.s.
Men ≤60 years -2.8 [-9.0,+3.5], n.s.a -1.2 [-7.3,+5.0], n.s.a
Men 61-68 years +8.3 [+0.4,+16.1]* a +1.8 [-5.9,+9.5], n.s.a
Urinary irritative/obstructive +1.6 [-1.0,+4.2], n.s. +1.6 [-1.1,+4.2], n.s. +1.0 [-1.5,+3.6], n.s. +1.5 [-1.1,+4.1], n.s.
Bowel -0.5 [-3.0,+2.0], n.s. +0.1 [-2.4,+2.6], n.s. -0.2 [-2.6,+2.2], n.s. -0.3 [-2.7,+2.1], n.s.
Hormonal +1.9 [-1.0,+4.8], n.s. -0.5 [-3.2,+2.1], n.s. +2.9 [+0.1,+5.7]* -0.1 [-2.7, +2.5], n.s.
EDITS total +0.3 [+0.1,+0.6]** +0.3 [+0.02,+0.5]* +0.2 [+0.01,+0.5]* +0.1 [-0.1,+0.4], n.s.
SEAR sexual relationship +1.8 [-0.3,+3.8], n.s. +0.2 [-2.2,+2.5], n.s. +0.5 [-1.5,+2.5], n.s. -0.04 [-2.3,+2.3], n.s.
SEAR confidence +0.4 [-1.2,+1.9], n.s. +0.1 [-1.6,+1.8], n.s. +0.4 [-1.1,+1.9], n.s. +0.2 [-1.5,+1.8], n.s.
LS mean treatment group difference versus placebo: **: p <0.01 ; *: p <0.05; n.s.: not significant (p>0.05)
Figure 2 Summary of treatment group differences between tadalafil OaD and tadalafil PRN versus placebo at the end of DBT and OLT. aFor men
≤ 60 years and 61–68 years, the overall treatment effect presented includes all visits from baseline to end of OLT. Data are from MMRM models,
including baseline value (except for EDITS), treatment, country, visit, visit-by-treatment interaction, and age group (men ≤60 years, men 61–68 years).
The MMRM assessing the combined sexual/incontinence score (post-hoc) additionally adjusted for body mass index, smoking status, nerve-sparing
score, and type of surgery (open, conventional, robot-assisted, other). Age-group-by-treatment interaction was included in the models only if significant
at the 10% level.
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consistent with these findings.EPIC domain scores – patient-partner agreement
Approximately one-third (N = 153) of patients’ partners
attended the study visits and completed the EPIC
partner questionnaire. Patient-partner agreement could
only be assessed for approximately one-third of pa-
tients (e.g., partner and patient baseline EPIC sexual
domain score available for 140 of 422 patients, 33.2%).
Agreement between patients and partners’ ratings was
poor (0 to 0.2) to moderate (0.4 to 0.6) for the different
time points and domains assessed; no definite pattern
of agreement was observed.Treatment satisfaction
Treatment satisfaction (EDITS total scores) increased
significantly in both tadalafil groups when compared
with placebo at the end of DBT (OaD versus placebo:
0.33 [0.10,0.56]; p = 0.005, and PRN versus placebo: 0.23
[0.01,0.45]; p = 0.041) (Figure 2,4). At the end of OLT,
improvement was only significant for tadalafil OaD
versus placebo (p = 0.035). Unadjusted data for EDITS
total scores were consistent (Additional file 1: Table S3).
No significant treatment group differences were ob-
served for SEAR (Additional file 1: Tables S4 and S5).Discussion
Any major surgery is expected to reduce overall patient
QoL during the initial stages of healing and rehabilitation,
this is enhanced by the psychosocial impact of a cancer
diagnosis. Patients after nsRP face additional challenges,
namely impaired EF and urinary continence, which may
continue to affect their QoL long after the initial healing
phase is complete [17,18]. This can be particularly difficult
for younger patients who may be more sexually active
than the elderly population. Patients are faced with a long
period of time during which sexual and urinary function is
not entirely regained, substantially impacting QoL not
only for the patients recovering from nsRP but also for
their partners [19].
As reported previously, 9 months of DBT with tadala-
fil OaD, but not tadalafil PRN, significantly increased
and accelerated EF recovery when compared with
placebo [9,20]; improvements in IIEF-EF and SEP-3
exceeded the minimum clinically relevant difference
(MCID) [9]. Treatment with tadalafil OaD treatment
was well tolerated; no new safety signals were detected
in the prostate cancer patient population [9]. This
analysis evaluated if tadalafil treatment affected the
patients’ perceived QoL in terms of sexual function
and urinary incontinence, as assessed by the respective
EPIC domain scores. During DBT, IIEF-EF, EPIC sexual
domain score, and EDITS score improved with tadalafil
Figure 3 EPIC Urinary Incontinence Score Changes from Baseline: (a) at the end of DBT (Month 9) and OLT (Month 13.5), and (b) overall mean
change in younger (<61 years) and older (61–68 years) patients, as estimated from MMRM. Data from MMRM model, adjusting for baseline
domain score, treatment, country, visit, visit-by-treatment interaction, age group, and age-group-by-treatment interaction. EPIC scores range from
0–100; higher scores indicate better values.
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This may be due to chronic (daily) tadalafil dosing that
would lead to steady-state PDE5-inhibition [21] and
may be associated with prolonged (continuous) periods
of increased tissue oxygenation during the post-operative
regenerative process.
During DBT, patient-rated EPIC sexual domain scores
improved in all 3 treatment groups by 27.5% with tadala-
fil OaD, 20.7% with tadalafil PRN, and 18.0% with
placebo. As for IIEF-EF and SEP-3 [9], the improvementwas statistically significant versus placebo (p = 0.004) in
the tadalafil OaD group only.
The LS mean difference in EPIC sexual domain score
changes between tadalafil OaD and placebo was 3.2
points; there is currently no general consensus on how
to define the MCID for EPIC domain scores. During the
3 months of additional OLT with tadalafil OaD, EPIC
sexual domain scores continued to improve, with overall
improvements of more than 30% from baseline to the
end of OLT in all 3 groups. The significant treatment
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Figure 4 EDITS Total Scores at the End of DBT (Month 9) and OLT (Month 13.5). Data from MMRM model, adjusting for treatment, country, visit,
visit-by-treatment interaction, age group, and age-group-by-treatment interaction. EDITS total score ranges from 0–4; higher score indicates
better value.
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groups received active tadalafil OaD during OLT.
A significant age group-by-treatment interaction
(p = 0.084) indicated that in older patients only (61–68
years of age), EPIC urinary incontinence scores also sig-
nificantly improved with tadalafil OaD compared with pla-
cebo (no significant effect with PRN). The effect was not
observed in younger patients (<61 years of age),
potentially because they were less affected by urinary
incontinence symptoms. There are currently competing
hypotheses for the etiology of post-prostatectomy incon-
tinence [22]. Apart from the experience of the surgeon
and the surgical technique employed, the most relevant
pre-operative predictors of urinary incontinence following
robot-assisted nsRP as identified by a meta-analysis in-
cluded age, body mass index (BMI), comorbidity index,
lower urinary tract symptoms, and prostate volume
[23]. Urinary incontinence after nsRP is known to be a
long-term complication. In the prostate cancer outcome
study, 8.4% of all patients were incontinent at ≥18 months
after nsRP, even more (14%) had urinary incontinence
symptoms after 5 years [12,17]. In a recent study by Nam
et al. approximately 5% of patients required incontinence
surgery within 15 years post-nsRP [24]. In both studies, the
risk for late urinary complications post-nsRP also increased
with age [17,24]. In the elderly patients, a fair correlation
between EPIC urinary and sexual domain scores (highest
at baseline: r = 0.39) was observed in the current study.
Several clinical trials show that PDE5 inhibitors, includ-
ing tadalafil OaD, can reduce lower urinary tract symp-
toms in patients with benign prostate hyperplasia [25-27].A positive effect for PDE5 inhibitors on urinary contin-
ence following nsRP was initially observed in a retrospect-
ive study by Gandaglia et al. [28]. More recently, Gacci
et al. reported significantly improved urinary continence
in patients using vardenafil (nightly) compared with pla-
cebo in a prospective 12-month study (39 patients) [29].
It is not fully understood how PDE5 inhibitors might act
to improve bladder function, although improvements in
sphincteric and/or pelvic floor blood supply could be re-
sponsible for this effect [28,29]. Moreover, the human
bladder expresses high levels of PDE5, inhibition of which
can modulate bladder contractility through induction of
cyclic guanosine monophosphate [29,30]. The correlation
between EPIC urinary incontinence and sexual domain
scores decreased over time, potentially due to a differential
improvement of sexual and urinary scores.
The perception of the partner during couples’ sexual
recovery after nsRP has not been extensively studied,
although partners’ needs should be addressed as legit-
imate aspect of patient care [31]. In this study, only
33.2% of patients’ partners completed the EPIC ques-
tionnaire, no clear pattern of patient-partner agreement
could be derived. Findings in other studies have indi-
cated that partner QoL can be negatively impacted for
at least as long as a patient’s QoL following prostate
cancer treatment [19,32].
Although significant improvements in the EPIC sexual
and urinary incontinence domains were only observed
for tadalafil OaD treatment, treatment satisfaction at the
end of DBT, as measured by the EDITS questionnaire,
was significantly improved following both tadalafil OaD
Patel et al. BMC Urology  (2015) 15:31 Page 9 of 10and PRN administration relative to placebo. However, at
the end of OLT, improvement in treatment satisfaction
was only significant for tadalafil OaD versus placebo.
There were several potential limitations of the current
study. One important consideration is that the patient
group selected may not have been ideal for observing an
effect on EF or urinary incontinence with chronic tada-
lafil administration. Patients were on average relatively
young (58 years of age), sexually active, and had few
comorbidities, thus possibly representing a population
of patients who might have shown improvement of EF
and urinary continence rates after nsRP without treat-
ment [33]. This could result in dilution of an effect of
tadalafil on QoL, and might explain why tadalafil OaD
administration significantly improved EPIC urinary in-
continence domain scores versus placebo in the elderly
population (61 to 68 years) only. Thus, future studies
with different patient populations (older, less fit) could
help clarify the effect of tadalafil OaD treatment on
QoL in post-nsRP patients.
Additional limitations were imposed by the study
design. First, the 9-month DBT period may have been too
short for optimal assessment of EF recovery, sexual
function, urinary incontinence, and associated QoL.
After 9 months of DBT, low EF recovery rates of 25.2%,
19.7%, and 14.2% for tadalafil OaD, tadalafil PRN, and pla-
cebo, respectively, were observed [9]. In contrast, a retro-
spective study from Briganti et al. found 3-year EF recovery
rates following nsRP of 72% in patients receiving PDE5 in-
hibitors versus 38% in patients receiving placebo [1], and a
recent sildenafil study found recovery rates of around 40%
following 12 months of treatment [34]. Second, EPIC scores
were not assessed at the end of the drug-free washout
period, but only at the end of DBT and OLT. Thus, sexual
function and urinary incontinence after treatment cessation
could not be assessed. Also, no valid conclusions are
possible regarding the patient-partner agreement for EPIC
domain scores since only one-third of the partners
completed the questionnaire. Finally, the only source for
the data on urinary incontinence was the respective EPIC
domain score. EPIC data were collected to evaluate
patients’ disease-specific QoL; standard instruments for
assessment of urinary function, such as the International
Prostate Symptom Score might be better suited to evaluate
the impact of PDE5 inhibitor treatment on urinary
function.Conclusion
Chronic dosing of tadalafil started early after nsRP increases
and accelerates EF recovery [9,20] and also improves
patients’ QoL. The improvement of urinary incontin-
ence facilitated by tadalafil OaD specifically in elderly
patients may contribute to this effect on QoL.Additional file
Additional file 1: Table S1. List of Ethical Review Boards. Table S2.
Arithmetic mean EPIC domain score changes (patient). Table S3.
Arithmetic mean EDITS total scores. Table S4. LSmean changes [95% CI]
in SEAR domain scores from baseline. Table S5. Arithmetic mean SEAR
scores. Figure S1. Trial design. Figure S2. Patient disposition.
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